Quiroga, BorjaSoler, María JoséOrtiz, AlbertoMartínez Vaquera, ShairaJarava Mantecón, Carlos JesúsUseche, GustavoSánchez Márquez, María GabrielaCarnerero, ManuelJaldo Rodríguez, María TeresaMuñoz Ramos, PatriciaRuiz San Millán, Juan CarlosToapanta, NestorGracia-Iguacel, CarolinaAguilar Cervera, María CintaBalibrea Lara, NoeliaLeyva, AlbaRojas, JoséGansevoort, Ron Tde Sequera, PatriciaSENCOVAC Collaborative Network2023-05-032023-05-032022http://hdl.handle.net/10668/19817Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P  The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.enCOVID-19SARS-CoV-2antibodieshumoral responsevaccineAntibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesHumansProspective StudiesRenal Insufficiency, ChronicSARS-CoV-2research article34788858open access10.1093/ndt/gfab3131460-2385PMC8767866https://pure.rug.nl/ws/files/252748650/Safety_and_immediate_humoral_response_of_COVID_19_vaccines_in_chronic_kidney_disease_patients_the_SENCOVAC_study.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767866/pdf